COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB PLUS CHEMOTHERAPY VS CHEMOTHERAPY IN PATIENTS WITH ADVANCED GASTRIC CANCER IN JAPAN

被引：0
|
作者：
Morimoto, K. [1 ]
Moriwaki, K. [2 ]
Shimozuma, K. [3 ]
Nakayama, T. [1 ]
机构：
[1] Kyoto Univ, Kyoto, Japan
[2] Ritsumeikan Univ, Kyoto 26, Japan
[3] Ritsumeikan Univ, Kusatsu, Japan
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HTA7
引用
收藏
页码：S505 / S505
页数：1
相关论文
共 50 条
  • [21] Nivolumab plus chemotherapy for advanced gastric cancer and oesophageal adenocarcinoma
    Hindson J.
    Nature Reviews Gastroenterology & Hepatology, 2021, 18 (8) : 523 - 523
  • [22] Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced NSCLC
    Li, Jiahao
    Zhang, Tiantian
    Xu, Yongmei
    Lu, Peiyao
    Zhu, Jiaxin
    Liang, Wenhua
    Jiang, Jie
    IMMUNOTHERAPY, 2020, 12 (14) : 1067 - 1075
  • [23] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB plus CHEMOTHERAPY FOR PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER IN JAPAN
    Akai, M.
    Moriwaki, K.
    Morimoto, K.
    Shimozuma, K.
    VALUE IN HEALTH, 2024, 27 (06) : S69 - S69
  • [24] Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
    Hu, Huabin
    She, Longjiang
    Liao, Mengting
    Shi, Yin
    Yao, Linli
    Ding, Dong
    Zhu, Youwen
    Zeng, Shan
    Carbone, David P.
    Huang, Jin
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [25] Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy as the first-line treatment for advanced esophageal cancer
    Ye, Zhuo-Miao
    Xu, Zhe
    Wang, Hao-Lun
    Wang, Ying-Yuan
    Chen, Ze-Chang
    Zhou, Qin
    Li, Xiang-Ping
    Zhang, Ying-Ying
    CANCER MEDICINE, 2023, 12 (05): : 6182 - 6189
  • [26] Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer
    Huo, Gengwei
    Song, Ying
    Liu, Wei
    Guo, Hua
    Chen, Peng
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [27] Cost-effectiveness of Paclitaxel plus Ramucirumab Combination Therapy for Advanced Gastric Cancer Progressing After First-line Chemotherapy in Japan
    Saito, Shota
    Muneoka, Yusuke
    Ishikawa, Takashi
    Akazawa, Kouhei
    CLINICAL THERAPEUTICS, 2017, 39 (12) : 2380 - 2388
  • [28] Efficacy and cost-effectiveness of second-line chemotherapy in elderly patients with advanced gastric cancer
    K. Zhou
    F. Wen
    P. Zhang
    J. Zhou
    H. Chen
    H. Zheng
    Y. Yang
    Q. Li
    Clinical and Translational Oncology, 2017, 19 : 1117 - 1124
  • [29] Efficacy and cost-effectiveness of second-line chemotherapy in elderly patients with advanced gastric cancer
    Zhou, K.
    Wen, F.
    Zhang, P.
    Zhou, J.
    Chen, H.
    Zheng, H.
    Yang, Y.
    Li, Q.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (09): : 1117 - 1124
  • [30] EFFICACY AND COST-EFFECTIVENESS OF SECOND-LINE CHEMOTHERAPY IN ELDERLY PATIENTS WITH ADVANCED GASTRIC CANCER
    Zhou, K.
    VALUE IN HEALTH, 2017, 20 (09) : A871 - A871
12345